Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Ana C. Garrido-Castro(Dana-Farber Cancer Institute), Sara M. Tolaney(Harvard University), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Molly DiLullo(Dana-Farber Brigham Cancer Center), Eileen Wrabel(Dana-Farber Cancer Institute), Lestat R. Ali(Dana-Farber Cancer Institute), Geoffrey I. Shapiro(Brigham and Women's Hospital), Nabihah Tayob(Dana-Farber Cancer Institute), Amy J. Williams(University of Florida), Christina I. Herold(Beth Israel Deaconess Medical Center), Heather A. Parsons(Harvard University), Noah Graham(Dana-Farber Cancer Institute), Tianyu Li(Dana-Farber Cancer Institute), Khanh Do(Harvard University), Jennifer Desrosiers(Dana-Farber Cancer Institute), Stephanie K. Dougan(Dana-Farber Cancer Institute), Joyce F Liu(Harvard University), Shom Goel(Dana-Farber Cancer Institute)
Cited by 15
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
|Cancer Discovery|2019|1.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k